# A Study of GQ1010 in Subjects With Advanced Solid Tumors

> **NCT06464055** · PHASE1,PHASE2 · RECRUITING · sponsor: **GeneQuantum Healthcare (Suzhou) Co., Ltd.** · enrollment: 260 (estimated)

## Conditions studied

- Advanced Malignant Solid Tumors

## Interventions

- **DRUG:** Dose Escalation
- **DRUG:** Dose Expansion1
- **DRUG:** Dose Expansion2
- **DRUG:** Dose Expansion3
- **DRUG:** phase II

## Key facts

- **NCT ID:** NCT06464055
- **Lead sponsor:** GeneQuantum Healthcare (Suzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-05-23
- **Primary completion:** 2028-05-23
- **Final completion:** 2028-12-31
- **Target enrollment:** 260 (ESTIMATED)
- **Last updated:** 2025-02-10


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06464055

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06464055, "A Study of GQ1010 in Subjects With Advanced Solid Tumors". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06464055. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*